Allogeneic Transplantation
Eligibility: Ages ≥ 18; Subject must have confirmation of non-APL AML by WHO criteria and have been treated with first-line venetoclax/HMA (azacitidine or decitabine)
Eligibility: Ages ≥ 18 years; R/R AML; ECOG of ≤2
Eligibility: acute leukemia; not eligible for participation in an ongoing clinical study and have no approved treatment options.
Eligibility: Ages ≥ 18; documented NPM1 mutation or KMT2A rearrangement and have either newly diagnosed or relapsed/refractory AML; ECOG of ≤2
Eligibility: Ages 18-59; untreated AML; ECOG of ≤2
Eligibility: Ages ≥ 18 years; non-APL AML and at least one line of therapy; ECOG of ≤ 2
Eligibility: Ages ≥ 18 years; Relapsed or refractory AML with myelomonocytic or monoblastic/monocytic differentiation and has failed treatment with available therapies known to be active for AML; Relapsed or refractory LILRB4high AML with myelomonocytic or monoblastic/monocytic differentiation and has failed treatment with available therapies known to be active for AML; Newly diagnosed high LILRB4 expression monocytic AML patients considered to be ineligible for standard induction therapy; ECOG of ≤ 2
Eligibility: Ages ≥ 18 years; non-APL AML who have not responded to or relapsed after at least one prior therapy and for whom no standard therapy that may provide clinical benefit is available; ECOG of ≤ 2
Eligibility: high risk AML patients based on the following inclusion criteria: • Newly diagnosed with AML at the age of 60 or greater • Antecedent hematologic disorder (prior blood disorder before AML diagnosis) • Therapy-related disease (radiation / chemotherapy for another cancer before AML diagnosis) • Relapse AML or primary refractory AML • Patient’s AML went into remission and came back • Patient received AML treatment and did not go into remission
Eligibility: Ages ≥ 18 years; untreated non-acute promyelocytic leukemia (APL) AML with a bone marrow or peripheral blood blast count ≥20%; must be willing to undergo a blood sample for RARA biomarker investigational assay testing with confirmed RARA-positive results prior to C1D8
Eligibility: Ages ≥ 18; B-cell ALL in first complete morphologic remission; MRD positive; ECOG of ≤2
Eligibility: Ages ≥ 18 years; Active Acute Leukemia harboring MLL rearrangement or NPM1c mutation (Arm A, B); Active Acute Leukemia harboring MLL rearrangement, NUP98 rearrangement or NPM1c mutation (Arm C, D, E, F); R/R Acute Leukemia (Phase 1) R/R ALL/MPAL/AML with an MLLr translocation or AML with NPM1c (Phase 2), ECOG of ≤ 2
Eligibility: Ages ≥ 18 years; diagnosed R/R B-ALL; B-ALL blast expressing CD22; , ECOG of 0 or 1